Gain Therapeutics Inc.

NASDAQ: GANX · Real-Time Price · USD
1.73
0.19 (12.34%)
At close: Aug 15, 2025, 3:59 PM
1.76
1.73%
After-hours: Aug 15, 2025, 07:49 PM EDT

Gain Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a 55.18K 140.11K 164.99K
Cost of Revenue
84.07K 80.38K 64.17K 7.16M
Gross Profit
-84.07K -25.2K 75.94K -7M
Operating Income
-20.35M -22.25M -17.78M -13.83M
Interest Income
357.1K 494.23K 375.36K 12.49K
Pretax Income
-19.87M -22.19M -17.5M -13.89M
Net Income
-20.41M -22.27M -17.59M -13.89M
Selling & General & Admin
9.56M 10.79M 9.54M 6.83M
Research & Development
10.79M 11.52M 8.38M 7.16M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
20.35M 22.31M 17.92M 13.99M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
-20.35M 22.31M 17.92M 13.99M
Income Tax Expense
536.82K 79.28K 92.98K 4.01K
Shares Outstanding (Basic)
22.88M 13.01M 11.88M 10.17M
Shares Outstanding (Diluted)
22.88M 13.01M 11.88M 10.17M
EPS (Basic)
-0.89 -1.71 -1.48 -1.37
EPS (Diluted)
-0.89 -1.71 -1.48 -1.37
EBITDA
-19.79M -22.17M -17.78M -13.82M
EBIT
-19.87M -22.25M -17.78M -13.83M
Depreciation & Amortization
84.07K 83.58K 64.17K 15.48K